ANI Pharmaceuticals (BST:BSFA) - Aandelenkoers, Nieuws & Analyse

BSFA Overzicht aandelen

ANI Pharmaceuticals, Inc., een biofarmaceutisch bedrijf, ontwikkelt, produceert en verkoopt merkgeneesmiddelen en generieke geneesmiddelen op recept in de Verenigde Staten en Canada.

Over het bedrijf

BSFA fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 80.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 38.32% per jaar groeien

Dit jaar winstgevend geworden

Analisten zijn het erover eens dat de aandelenkoers met 34% zal stijgen

Risicoanalyse

Grote eenmalige posten die de financiële resultaten beïnvloeden

Aandeelhouders zijn het afgelopen jaar verwaterd

ANI Pharmaceuticals, Inc. Concurrenten

Dermapharm Holding

XTRA:DMP

€1.7b

PharmaSGP Holding

XTRA:PSG

€295.0m

Pierrel

DB:2FJ0

€92.8m

MPH Health Care

DB:93M1

€101.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ANI Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$53.00
52 Week Hoogtepunt	US$64.00
52 Week Laag	US$44.20
Bèta	0.71
11 maand verandering	1.92%
3 maanden verandering	-0.93%
1 Jaar Verandering	-10.17%
33 jaar verandering	23.83%
5 jaar verandering	1.92%
Verandering sinds IPO	1,016.49%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BSFA	DE Pharmaceuticals	DE Markt
7D	-0.9%	-1.7%	-1.8%
1Y	-10.2%	-12.7%	13.2%

Rendement versus industrie: BSFA overtrof de German Pharmaceuticals industrie, die het afgelopen jaar een rendement -12.7 % opleverde.

Rendement versus markt: BSFA presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 13.2 % opleverde.

Prijsvolatiliteit

Is BSFA's price volatile compared to industry and market?
BSFA volatility
BSFA Average Weekly Movement	6.2%
Pharmaceuticals Industry Average Movement	7.9%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: BSFA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van BSFA is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	642	Nikhil Lalwani	www.anipharmaceuticals.com

ANI Pharmaceuticals, Inc., een biofarmaceutisch bedrijf, ontwikkelt, produceert en verkoopt merkgeneesmiddelen en generieke geneesmiddelen op recept in de Verenigde Staten en Canada. Het bedrijf produceert producten in vaste vorm voor oraal gebruik, halfvaste, vloeibare en topicale toediening, gereguleerde stoffen en krachtige producten, evenals contractontwikkeling en productie van farmaceutische producten. Het verkoopt zijn producten via apotheekketens, groothandelaren, distributeurs en postorderapotheken, collectieve inkooporganisaties, gespecialiseerde apotheken en ziekenhuizen.

ANI Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ANI Pharmaceuticals zich tot de beurswaarde?
BSFA fundamentele statistieken
Marktkapitalisatie	€1.05b
Inkomsten(TTM)	€21.16m
Inkomsten(TTM)	€497.35m

49.5x

Koers/Winstverhouding

2.1x

P/S-verhouding

Is BSFA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BSFA resultatenrekening (TTM)
Inkomsten	US$538.95m
Kosten van inkomsten	US$208.38m
Brutowinst	US$330.58m
Overige uitgaven	US$307.65m
Inkomsten	US$22.93m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 08, 2024

Winst per aandeel (EPS)	1.17
Brutomarge	61.34%
Nettowinstmarge	4.25%
Schuld/Eigen Vermogen Verhouding	59.4%

Hoe presteerde BSFA op de lange termijn?

Bekijk historische prestaties en vergelijking

BSFA Overzicht aandelen

Beloningen

Risicoanalyse

ANI Pharmaceuticals, Inc. Concurrenten

XTRA:DMP

€1.7b

XTRA:PSG

€295.0m

DB:2FJ0

€92.8m

DB:93M1

€101.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

Recent updates

ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Senior VP of Finance & CFO recently sold €292k worth of stock

President recently sold €1.0m worth of stock

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.93 (vs US$0.056 in 1Q 2023)

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Independent Director recently sold €420k worth of stock

Full year 2023 earnings released: EPS: US$0.95 (vs US$3.05 loss in FY 2022)

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of Rare Disease recently sold €148k worth of stock

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$0.51 (vs US$0.55 loss in 3Q 2022)

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

President recently sold €3.0m worth of stock

Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.94 loss in 2Q 2022)

Forecast breakeven date moved forward to 2023

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings released: EPS: US$0.063 (vs US$1.27 loss in 1Q 2022)

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Full year 2022 earnings released: US$3.05 loss per share (vs US$3.40 loss in FY 2021)

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

High number of new directors

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.37 loss in 3Q 2021)

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

Key Executive recently sold €661k worth of stock

ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings released: US$0.94 loss per share (vs US$1.17 loss in 2Q 2021)

Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary